ENDOPORE
Live / Registered — Registered (as of 27 May 2025)
What this means for you
Registered since 27 May 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79379326
- Registration number
- 7805555
- Mark type
- Stylized text
- Filed
- 25 Jul 2023
- Published for opposition
- 08 Apr 2025
- Registered
- 27 May 2025
- Attorney of record
- Jordan Arnot Leahey
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for intracellular delivery of drugs for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of drugs for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical preparations for gene editing; veterinary preparations for gene editing; pharmaceutical preparations for intracellular delivery of therapeutic substances focused on the development of RNA therapies for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of therapeutic substances focused on the development of RNA therapies for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery of therapeutic substances for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases focused on non-viral delivery technology; veterinary preparations for intracellular delivery of therapeutic substances for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases focused on non-viral delivery technology; pharmaceutical preparations for intracellular delivery of nucleic acids for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of nucleic acids for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery of proteins for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of proteins for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery of peptides for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of peptides for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery of small molecules for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of small molecules for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of drugs for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical substances for gene editing; pharmaceutical substances for intracellular delivery of therapeutic substances focused on the development of RNA therapies for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of therapeutic substances for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases focused on non-viral delivery technology; pharmaceutical substances for intracellular delivery of nucleic acids for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of proteins for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery peptides for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of peptides for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of small molecules for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical compositions and preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer
- Class 035 — Advertising and business services: Compilation of information into computer databases in the medical field
- Class 042 — Scientific and technological services: Scientific and technological services, namely, scientific research, technological research, and research and design, all in the fields of intracellular delivery of drugs, gene editing, intracellular delivery of therapeutic substances focused on the development of RNA therapies, intracellular delivery of therapeutic substances focused on non-viral delivery technology, intracellular delivery of nucleic acids, intracellular delivery of proteins, intracellular delivery of peptides, and intracellular delivery of small molecules; research services in the fields of intracellular delivery of drugs, gene editing, intracellular delivery of therapeutic substances focused on the development of RNA therapies, intracellular delivery of therapeutic substances focused on non-viral delivery technology, intracellular delivery of nucleic acids, intracellular delivery of proteins, intracellular delivery of peptides, and intracellular delivery of small molecules; clinical trials, namely, scientific research in the nature of conducting clinical trials for others; development of pharmaceutical preparations and medicines; laboratory research services relating to pharmaceuticals; medical research laboratories; medical research laboratory services; medical research; medical research services; pharmaceutical drug development services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of vaccines and medicines; research of pharmaceuticals; research relating to medicines; research relating to pharmaceuticals; scientific investigations for medical purposes; scientific research and development; scientific research in the field of pharmacy; medical research, namely, services for assessing the efficacy of pharmaceuticals; information, advisory and consultancy services relating to all of the aforesaid
- Class 044 — Medical, beauty and agricultural services: Medical services; medical analysis for the diagnosis and treatment of persons; pharmacy advice, namely, preparation of prescriptions in pharmacies and providing medical advice related to pharmaceutics; advisory services relating to health; advisory services relating to medical services; health care, namely, arranging of medical treatment; consultancy relating to health care; health advice and information services; health care; health care services; health centres being health clinic services; health clinic services; information services relating to health care; medical information retrieval services; health care, namely, medical treatment services; medical health assessment services; health care, namely, preparation of reports relating to health care matters; professional consultancy relating to health; providing health information; provision of health care services; provision of medical services; provision of medical information relating to medical practitioners; provision of medical information relating to medical specialists; services for the provision of medical care information; information, advisory and consultancy services relating to all of the aforesaid
Owner
Prosecution history
- 08 Jan 2026 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 21 Dec 2025 — FINAL DISPOSITION NOTICE SENT TO IB
- 21 Dec 2025 — FINAL DISPOSITION PROCESSED
- 27 Aug 2025 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 27 May 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 27 May 2025 — REGISTERED-PRINCIPAL REGISTER
- 08 Apr 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 08 Apr 2025 — PUBLISHED FOR OPPOSITION
- 02 Apr 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 14 Mar 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 14 Mar 2025 — EXAMINER'S AMENDMENT ENTERED
- 14 Mar 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 14 Mar 2025 — EXAMINERS AMENDMENT E-MAILED
- 14 Mar 2025 — EXAMINERS AMENDMENT -WRITTEN
- 08 Mar 2025 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB